GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Buyback Yield %

GSTC (GlobeStar Therapeutics) Buyback Yield % : -18.28 (As of Dec. 12, 2024)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

GlobeStar Therapeutics's current buyback yield was -18.28%.


GlobeStar Therapeutics Buyback Yield % Historical Data

The historical data trend for GlobeStar Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Buyback Yield % Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.03 -3.01 -0.19 -4.07

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.85 -7.14 -7.62 -6.88 -

Competitive Comparison of GlobeStar Therapeutics's Buyback Yield %

For the Biotechnology subindustry, GlobeStar Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeStar Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's Buyback Yield % falls into.



GlobeStar Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

GlobeStar Therapeutics's Buyback Yield for the fiscal year that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.073) / 1.793016
=-4.07%

GlobeStar Therapeutics's annualized Buyback Yield for the quarter that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 4 / 1.24111
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Jun. 2024) data.


GlobeStar Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeStar Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550

GlobeStar Therapeutics Headlines

From GuruFocus

AngioSoma Moving Forward With Exciting New Products

By Marketwired Marketwired 03-09-2020